BRPI0519096A2 - Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez - Google Patents

Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez

Info

Publication number
BRPI0519096A2
BRPI0519096A2 BRPI0519096-7A BRPI0519096A BRPI0519096A2 BR PI0519096 A2 BRPI0519096 A2 BR PI0519096A2 BR PI0519096 A BRPI0519096 A BR PI0519096A BR PI0519096 A2 BRPI0519096 A2 BR PI0519096A2
Authority
BR
Brazil
Prior art keywords
protein
receptor
precursor
diagnosing
polypeptide
Prior art date
Application number
BRPI0519096-7A
Other languages
English (en)
Inventor
S Ananth Karumanchi
Vikas P Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of BRPI0519096A2 publication Critical patent/BRPI0519096A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

ÁCIDOS NUCLÉICOS E POLIPEPTÍDEOS éTEIS PARA O DIAGNàSTICO E TRATAMENTO DE COMPLICAÇÕES NA GRAVIDEZ. A presente invenção refere-se a métodos para o diagnóstico e tratamento de distúrbios hipertensivos relacionados à gravidez que incluem o uso de um polipeptídeo ou um ácido nucléico que codifica um polipeptídeo selecionado dos seguintes: proteína relacionada à folistatina, interleucina 8, inibina A, VEGF-C, angiogenina, beta-fertilina, proteína hipotética, proteína secretada por receptor similar à lg associada a leucócito, proteína de diferenciação de eritróide, fator inibidor de adipogênese, proteína de ligação de fator de liberação de corticotropina, alfa-1 antiquimotripsina, proteina-5 de ligação de fator de crescimento similar à insulina, CD33L, fator 1 similar a receptor de citocina, fator de crescimento endotelial derivado de plaqueta, lisil hidrolase isoforma 2, precursor de estaniocalcina, proteína frizzled. relacionada secretada, galectina-3, esperminina oxidase, polipeptídeo B28 da família 2 de UDP glicosiltransferase, receptor de tirosina quinase neurotrófica, endopeptidase neutral, subunidade 2 reguladora de CDC28 proteína quinase, beta-glicosidase, alfa defensina, ADAM-TS3, precursor de colecisto- quinina, precursor de alfa-quimioatrativo de célula T estimulado por interferon, azurocidina, lanosterol sintase, serina proteína quinase dependente de cálcio/calmodulina, transcrito H unido alternativamente a receptor de estrogênio, receptor 1 de quimiocina (motivo CX3C), proteína 1 relacionada à tirosinase, hidróxi-delta-5-esteróide desidrogenase, diid ropiramidinase-similar- 4, e família-11 de citocromo P450.
BRPI0519096-7A 2004-12-15 2005-12-15 Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez BRPI0519096A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63627504P 2004-12-15 2004-12-15
PCT/US2005/045805 WO2007053161A2 (en) 2004-12-15 2005-12-15 Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy

Publications (1)

Publication Number Publication Date
BRPI0519096A2 true BRPI0519096A2 (pt) 2008-12-23

Family

ID=38006337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519096-7A BRPI0519096A2 (pt) 2004-12-15 2005-12-15 Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez

Country Status (11)

Country Link
US (1) US7955805B2 (pt)
EP (1) EP1839057B1 (pt)
JP (1) JP2008523816A (pt)
KR (1) KR20070092737A (pt)
CN (1) CN101299962A (pt)
AT (1) ATE478602T1 (pt)
AU (1) AU2005337873A1 (pt)
BR (1) BRPI0519096A2 (pt)
CA (1) CA2591142A1 (pt)
DE (1) DE602005023216D1 (pt)
WO (1) WO2007053161A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034507A2 (en) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
ATE519109T1 (de) 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
US7230561B2 (en) * 2005-01-27 2007-06-12 Micron Technology, Inc. Programmable integrating ramp generator and method of operating the same
CA2602963A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
CN101616927A (zh) * 2005-09-15 2009-12-30 迪爱麦有限公司 诊断先兆子痫的方法
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
WO2008089520A1 (en) * 2007-01-25 2008-07-31 Crc For Asthma And Airways Ltd Method of diagnosis
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
EP2037278A1 (en) * 2007-09-11 2009-03-18 F.Hoffmann-La Roche Ag Vascular markers in the remodelling of cardiac injury
US20110171650A1 (en) * 2008-09-16 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Gene expression related to preeclampsia
CN105021821B (zh) 2008-10-31 2018-05-11 耶鲁大学 先兆子痫检测和治疗的方法和组合物
CN102300875B (zh) * 2009-01-28 2014-07-16 财团法人工业技术研究院 肾病相关的生物标记
WO2012125641A1 (en) 2011-03-17 2012-09-20 Cedars-Sinai Medical Center Diagnostic biomarker to predict women at risk for preterm delivery
AU2011311997A1 (en) * 2010-02-26 2013-04-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3336552A3 (en) * 2010-11-29 2018-07-25 Mote Marine Laboratory, Inc. Fish sexual characteristic determination using peptide hormones
KR101114446B1 (ko) * 2011-02-25 2012-02-24 건국대학교 산학협력단 프로테오믹스기법을 이용한 임신중독 특이 표지 단백질 및 진단방법
CN102192987B (zh) * 2011-02-25 2014-04-02 复旦大学附属上海市第五人民医院 一种用于妊娠高血压疾病诊断的试剂盒
AU2012346594B2 (en) * 2011-11-30 2017-12-21 Agency For Science, Technology And Research GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring
JP2015505368A (ja) * 2012-01-06 2015-02-19 ビージー メディシン， インコーポレイテッド 妊娠高血圧腎症および関連状態のリスク評価および検出のためのガレクチン−３の使用
CN104634982B (zh) * 2013-11-06 2016-08-17 中国科学院上海生命科学研究院 Vegf-c在制备败血症及重症细菌感染诊断试剂中的用途
CN103760340B (zh) * 2014-01-28 2016-11-23 成都创宜生物科技有限公司 以flrg作为标志物制备检测工具的应用及检测工具
ES2817417T3 (es) 2014-04-10 2021-04-07 Univ Yale Métodos y composiciones para la detección de proteínas mal plegadas
US20160130553A1 (en) 2014-05-15 2016-05-12 Kellbenx Incorporated PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING
US12202890B1 (en) 2014-11-07 2025-01-21 Kellbenx Incorporated Antibodies for detection and enrichment of fetal cells and their use
ES2955883T3 (es) 2015-06-19 2023-12-07 Sera Prognostics Inc Pares de biomarcadores para la predicción del parto prematuro
CN106771266A (zh) * 2017-01-12 2017-05-31 广州市丰华生物工程有限公司 抑制素a定量检测试剂盒及其制备方法
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
US12436155B2 (en) * 2020-04-16 2025-10-07 Kalia Health, Inc. Preeclampsia screening device and methods measuring activin and/or inhibin A
CN111951969A (zh) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Hbp在高危妊娠预测中的应用
CN114075281B (zh) * 2021-11-16 2023-04-18 福州迈新生物技术开发有限公司 抗Inhibin-α蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) * 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) * 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
US6620590B2 (en) * 1996-07-11 2003-09-16 Isis Innovation Limited Diagnosis of pre-eclampsia
AU5331298A (en) 1996-12-23 1998-07-17 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US6376199B1 (en) * 1997-03-07 2002-04-23 The Hospital For Sick Children (Hsc) Methods to diagnose a required regulation of trophoblast invasion
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
EP1417971A3 (en) 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) * 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
WO2003057916A2 (en) * 2002-01-09 2003-07-17 Riken Cancer profiles
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20050266409A1 (en) 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
DE10333105B3 (de) * 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
WO2005017192A2 (en) * 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
AU2004276791B2 (en) * 2003-09-23 2010-07-01 Beth Israel Deaconess Medical Center Screening for gestational disorders
WO2006034507A2 (en) * 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
ATE519109T1 (de) * 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
JP2009538915A (ja) 2006-05-31 2009-11-12 ベス イスラエル ディーコネス メディカル センター 妊娠の合併症を診断および治療する方法

Also Published As

Publication number Publication date
ATE478602T1 (de) 2010-09-15
CA2591142A1 (en) 2007-05-10
WO2007053161A2 (en) 2007-05-10
WO2007053161A3 (en) 2007-11-29
EP1839057B1 (en) 2010-08-25
US20060166277A1 (en) 2006-07-27
AU2005337873A1 (en) 2007-05-10
HK1115286A1 (en) 2008-11-28
CN101299962A (zh) 2008-11-05
DE602005023216D1 (de) 2010-10-07
EP1839057A4 (en) 2008-12-31
KR20070092737A (ko) 2007-09-13
JP2008523816A (ja) 2008-07-10
US7955805B2 (en) 2011-06-07
EP1839057A2 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
EP1839057A4 (en) NUCLEIC ACIDS AND POLYPEPTIDES FOR THE DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS
JP2008523816A5 (pt)
Sonderegger et al. Complex expression pattern of Wnt ligands and frizzled receptors in human placenta and its trophoblast subtypes
Kobayashi et al. The ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian endometriosis
WO2022159520A3 (en) Methods for biomolecule quantitation
Taube et al. Foxa1 functions as a pioneer transcription factor at transposable elements to activate Afp during differentiation of embryonic stem cells
Vogt et al. ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth
Xu et al. Expression of TGF-β signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells
Zhao et al. Bone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial‐like tube formation through ID1‐mediated upregulation of IGF binding protein‐3
Bumke et al. Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study
Li et al. DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells
JP2010512730A5 (pt)
Zhang et al. XCL 1‐XCR 1 pathway promotes trophoblast invasion at maternal‐fetal interface by inducing MMP‐2/MMP‐9 activity
Brkić et al. Differential role of Smad2 and Smad3 in the acquisition of an endovascular trophoblast-like phenotype and preeclampsia
Nagashima et al. Hepatocyte growth factor (HGF), HGF activator, and c-Met in synovial tissues in rheumatoid arthritis and osteoarthritis.
US8592223B2 (en) Use of periostin as a novel biomarker
Xu et al. Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells
AU3618095A (en) Alk-7 (activin like kinase), a serine threonine kinase receptor
Jemelkova et al. GalNAc-T14 may contribute to production of galactose-deficient immunoglobulin A1, the main autoantigen in IgA nephropathy
KR102438838B1 (ko) 류마티스 관절염 진단용 바이오마커
GB2424947A (en) Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells
Liu et al. Endothelin-1 stimulates human trophoblast cell migration through Cdc42 activation
Lee et al. AIMP1/p43 downregulates TGF-β signaling via stabilization of smurf2
Kasahara et al. Primate-specific POTE-actin gene could play a role in human folliculogenesis by controlling the proliferation of granulosa cells
Vatinel et al. An ITIM-like motif within the CCK2 receptor sequence required for interaction with SHP-2 and the activation of the AKT pathway

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2202 DE 19/03/2013.